## **Core Concept**
Psoralen-A, also known as methoxsalen, is a medication used in conjunction with ultraviolet A (UVA) light therapy. It belongs to a class of drugs known as **psoralens**, which are **photosensitizing agents**. When exposed to UVA light, psoralens increase the skin's sensitivity to ultraviolet light, thereby enhancing the therapeutic effects of UVA exposure.

## **Why the Correct Answer is Right**
The correct answer, **C. Vitiligo**, is a condition characterized by the loss of skin pigment cells, called melanocytes. Psoralen-A, when used with UVA light (PUVA therapy), helps stimulate repigmentation of the skin. The mechanism involves the intercalation of psoralen into DNA, which, upon UVA exposure, forms covalent bonds with DNA. This leads to the activation of melanocytes and subsequent repigmentation of the affected skin areas.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While PUVA therapy can be used for **psoriasis**, it's not the most specifically associated condition with Psoralen-A compared to vitiligo. Psoriasis treatment often involves a variety of modalities, including topical treatments, light therapy, and systemic medications.
- **Option B:** **Leukemia** treatment involves a wide range of chemotherapeutic agents and targeted therapies. Psoralen-A is not primarily used in the treatment of leukemia.
- **Option D:** **Graft-versus-host disease (GVHD)** management includes immunosuppressive drugs and supportive care. While UV light therapy can be used for certain symptoms of GVHD, Psoralen-A is specifically noted for its use in dermatological conditions like vitiligo.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **PUVA therapy**, which includes Psoralen-A, requires careful monitoring due to potential side effects such as **nausea**, **increased risk of skin cancer**, and **cataracts**. Patients undergoing PUVA therapy must be advised on strict sun protection measures.

## **Correct Answer:** . Vitiligo